Your browser doesn't support javascript.
Thrombotic thrombocytopenic purpura following administration of the Moderna booster vaccine.
Herrman, Emma; Ghimire, Bipin; Chisti, Mohammad Muhsin.
  • Herrman E; Internal Medicine, Beaumont Health, Royal Oak, Michigan, USA emma.herrman@beaumont.org.
  • Ghimire B; Internal Medicine, Beaumont Health, Royal Oak, Michigan, USA.
  • Chisti MM; Hematology and Medical Oncology, Oakland University William Beaumont School of Medicine, Troy, Michigan, USA.
BMJ Case Rep ; 15(3)2022 Mar 24.
Article in English | MEDLINE | ID: covidwho-1765101
ABSTRACT
Thrombotic thrombocytopenic purpura (TTP) is a type of thrombotic microangiopathy that is characterized by microangiopathic haemolytic anaemia, consumption thrombocytopenia and organ injury. It is caused by a severe deficiency of ADAMTS13, which can be either congenital or acquired. There is a plethora of things that can cause the acquired form, including medications and infections. Vaccines have also been shown to cause TTP. In the midst of the COVID-19 pandemic, with multiple new vaccines being developed and distributed to the masses, the medical community needs to be aware of adverse events associated with these new vaccines. We present a case of TTP following administration of the Moderna booster vaccine.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Purpura, Thrombotic Thrombocytopenic / COVID-19 / Anemia, Hemolytic Type of study: Case report / Observational study Topics: Long Covid / Vaccines Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: Bcr-2021-247576

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Purpura, Thrombotic Thrombocytopenic / COVID-19 / Anemia, Hemolytic Type of study: Case report / Observational study Topics: Long Covid / Vaccines Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: Bcr-2021-247576